Viking Therapeutics Inc. ($VKTX) announced that it has received encouraging preclinical results for NASH candidate VK2809. The stock reacted positively to the news and closed 5 percent higher. In a mouse model of diet-induced NASH, treatment with orally available VK2809 for eight weeks resulted in statistically significant improvements in non-alcoholic fatty liver disease activity score. It also showed statistically significant improvements for liver collagen content and liver fibrosis compared to controls.
VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders
<p align="left"><span style="line-height: 1.5;">